KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Cash (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Change in Cash for 15 consecutive years, with -$17.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 180.88% year-over-year to -$17.9 million, compared with a TTM value of $34.5 million through Dec 2025, up 9510.03%, and an annual FY2025 reading of $34.5 million, up 9510.03% over the prior year.
  • Change in Cash was -$17.9 million for Q4 2025 at Travere Therapeutics, down from $35.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $99.7 million in Q1 2023 and bottomed at -$90.5 million in Q2 2023.
  • Average Change in Cash over 5 years is $413150.0, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Change in Cash surged 1284.68% in 2021, then plummeted 681.16% in 2022.
  • Year by year, Change in Cash stood at $15.4 million in 2021, then tumbled by 681.16% to -$89.6 million in 2022, then rose by 3.99% to -$86.1 million in 2023, then surged by 125.71% to $22.1 million in 2024, then tumbled by 180.88% to -$17.9 million in 2025.
  • Business Quant data shows Change in Cash for TVTX at -$17.9 million in Q4 2025, $35.8 million in Q3 2025, and $13.3 million in Q2 2025.